Cite
HARVARD Citation
Hidalgo, M. et al. (n.d.). 361 Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1-3 and 15-17 every 28 days to patients with advanced malignant solid tumors. European journal of cancer. pp. S74-. [Online].